for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Evotec SE

EVTG.DE

Latest Trade

25.38EUR

Change

0.09(+0.36%)

Volume

860,389

Today's Range

25.36

 - 

25.82

52 Week Range

18.14

 - 

27.29

As of on the XETRA ∙ Minimum 15 minute delay

Latest Developments

Evotec Increases 2019 Adjusted EBITDA Guidance

Jan 20 (Reuters) - EVOTEC SE <EVTG.DE>::INCREASE OF PROFITABILITY GUIDANCE FOR FINANCIAL YEAR 2019.NOW EXPECTS AN INCREASE OF ADJUSTED GROUP EBITDA* BY MORE THAN 25% (PREVIOUSLY: IMPROVE BY APPROX. 15%) FOR 2019 COMPARED TO PREVIOUS YEAR (2018: EUR 92.0 M)..ALL OTHER ELEMENTS OF COMPANY'S FINANCIAL GUIDANCE ARE CONFIRMED.ADJUSTMENT DUE TO OPERATING PERFORMANCE IN Q4 2019 AND HIGH MILESTONE REVENUES FROM PARTNERSHIPS SUCH AS THOSE WITH CELGENE, BAYER AND SANOFI IN DEC 2019.

Bayer And Evotec Enter Alliance Focusing On Polycystic Ovary Syndrome

Jan 9 (Reuters) - EVOTEC SE <EVTG.DE>::BAYER AND EVOTEC FORM NEW STRATEGIC ALLIANCE FOCUSING ON POLYCYSTIC OVARY SYNDROME.MILESTONE PAYMENTS POTENTIALLY MORE THAN EUR 330 M, EUR 16.5 M IN UPFRONT AND RESEARCH PAYMENTS.FIVE-YEAR, MULTI-TARGET ALLIANCE.

Evotec Expands Strategic Partnership With Celmatix

Dec 3 (Reuters) - Evotec SE <EVTG.DE>::DGAP-NEWS: EVOTEC EXPANDS STRATEGIC PARTNERSHIP WITH CELMATIX IN WOMEN'S HEALTH.EVOTEC INVESTS IN A FINANCING ROUND ALONGSIDE INVESTORS INCLUDING LIFE SCIENCES INNOVATION FUND AND TOPSPIN FUND.PARTNERSHIP BUILDS ON EXISTING EVOTEC-CELMATIX-ALLIANCE IN WOMEN'S HEALTH.CELMATIX LEVERAGING PROPRIETARY MULTI-OMICS DATA PLATFORM FOR THERAPEUTIC DRUG DEVELOPMENT.NO FINANCIAL TERMS OF THIS COLLABORATION WERE DISCLOSED.

Merck Signs License Agreement With Evotec

Nov 12 (Reuters) - MERCK KGAA <MRCG.DE>::IT HAS SIGNED A LICENSE AGREEMENT PROVIDING EVOTEC SE ACCESS TO MERCK’S FOUNDATIONAL CRISPR INTELLECTUAL PROPERTY.

Evotec Raises 2019 EBITDA Guidance, Confirms Revenue Outlook

Nov 12 (Reuters) - Evotec SE <EVTG.DE>::EVOTEC SE REPORTS FIRST NINE-MONTH 2019 RESULTS AND CORPORATE UPDATES.16% INCREASE IN GROUP REVENUES, 36% GROWTH IN ADJUSTED GROUP EBITDA.REVENUE GUIDANCE FOR FULL-YEAR 2019 CONFIRMED; EBITDA GUIDANCE INCREASED TO APPROXIMATELY 15%; PROMISING INITIAL OUTLOOK FOR 2020.ADJUSTED GROUP EBITDA UP 36% TO EUR 93.2 M (9M 2018: EUR 68.7 M).UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES OF EUR 25.7 M (9M 2018: EUR 16.0 M).FULL-YEAR 2019 GUIDANCE FOR REVENUE AND UNPARTNERED RESEARCH AND DEVELOPMENT COSTS CONFIRMED; EBITDA GUIDANCE INCREASED TO APPROXIMATELY 15% (PREVIOUSLY: >10%).REVENUE INCREASE IN 9M MAINLY DUE TO VERY STRONG PERFORMANCE IN BASE BUSINESS ACROSS ALL BUSINESS LINES, SOLID MILESTONE PAYMENTS, AND FIRST REVENUE CONTRIBUTIONS BY JUST - EVOTEC BIOLOGICS.GROSS MARGIN IN FIRST NINE MONTHS OF 2019 AMOUNTED TO 30.7% (9M 2018: 30.1%).IMPAIRMENTS OF INTANGIBLE ASSETS AND GOODWILL OF EUR 11.9 M WERE RECORDED (9M 2018: IMPAIRMENT OF INTANGIBLE ASSETS OF EUR 4.2 M). THIS ONE-OFF IMPAIRMENT WAS MAINLY DUE TO TERMINATION OF SGM-1019 AGREEMENT BY OUR PARTNER SECOND GENOME.

Evotec Announces Partnership With Integra Holdings, Yissum

Oct 23 (Reuters) - Evotec SE <EVTG.DE>::EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT.FIRST ACADEMIC BRIDGE PARTNERSHIP IN ISRAEL AIMS TO TRANSLATE EARLY-STAGE RESEARCH FROM HEBREW UNIVERSITY ("HU") OF JERUSALEM INTO INDUSTRIAL DRUG DEVELOPMENT PROJECTS.LAB555 LEVERAGES INTEGRA'S SKILL IN IDENTIFYING AND DEVELOPING PROMISING EARLY-STAGE THERAPEUTIC PROJECTS, YISSUM'S TRANSLATIONAL EXPERTISE AND EVOTEC'S INDUSTRIAL DRUG DEVELOPMENT PLATFORM.NO FINANCIAL DETAILS OF COLLABORATION WERE DISCLOSED.

Evotec And Celmatix Enter Into Collaboration

Oct 9 (Reuters) - Evotec SE <EVTG.DE>::DGAP-NEWS: EVOTEC AND CELMATIX ENTER INTO STRATEGIC COLLABORATION.PARTNERSHIP TO DEVELOP PRE-CLINICAL PROGRAMMES IN PREVALENT BUT UNDERSERVED CONDITIONS AFFECTING WOMEN'S REPRODUCTIVE HEALTH, INCLUDING POLYCYSTIC OVARY SYNDROME ("PCOS"), ENDOMETRIOSIS, AND INFERTILITY.NO FINANCIAL TERMS OF THIS COLLABORATION WERE DISCLOSED.

Evotec, Takeda Enter Collaboration Across Multiple Therapeutic Fields

Sept 24 (Reuters) - Evotec Se <EVTG.DE>::DGAP-NEWS: EVOTEC AND TAKEDA ENTER COLLABORATION AGREEMENT TO DISCOVER CLINICAL CANDIDATES ACROSS MULTIPLE THERAPEUTIC AREAS.MULTI-YEAR SMALL MOLECULE DRUG DISCOVERY COLLABORATION WITH A RISK SHARING, SUCCESS DRIVEN MODEL.EVOTEC LEADS INTEGRATED PROGRAMMES WITH TAKEDA HAVING OPTIONS AT LEAD SERIES AND CANDIDATE.EVOTEC RECEIVES UNDISCLOSED UPFRONT PAYMENT AND CAN EARN FUTURE MILESTONE AND ROYALTY PAYMENTS.PARTIES AIM TO ESTABLISH AT LEAST FIVE DRUG DISCOVERY PROGRAMMES WITH GOAL OF EVOTEC DELIVERING CLINICAL CANDIDATES FOR TAKEDA TO PURSUE INTO CLINICAL DEVELOPMENT.EVOTEC IS ELIGIBLE TO RECEIVE PRE-CLINICAL, CLINICAL, AND COMMERCIAL MILESTONES THAT CAN TOTAL IN EXCESS OF $ 170 M PER PROGRAMME AS WELL AS TIERED ROYALTIES ON FUTURE SALES.

Evotec Lifts Guidance, Sees F-Y Operating Profit Rising by Over 10% After H1

Aug 14 (Reuters) - Evotec SE <EVTG.DE>::H1 REVENUE ROSE 16 PERCENT TO 207.1 MILLION EUR.DGAP-NEWS: EVOTEC SE REPORTS FIRST HALF-YEAR 2019 RESULTS AND CORPORATE UPDATES.STRONG OUTLOOK FOR YEAR - GUIDANCE INCREASED.STRONG FIRST HALF YEAR WITH 16% INCREASE IN GROUP REVENUES, 51% EBITDA.GROUP REVENUES UP 16% TO EUR 207.1 M (H1 2018: EUR 178.9 M).ADJUSTED GROUP EBITDA UP 51% TO EUR 58.2 M (H1 2018: EUR 38.6 M).UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES OF EUR 18.7 M (H1 2018: EUR 10.0 M).GROUP REVENUES FROM CONTRACTS WITH CUSTOMERS WITHOUT REVENUES FROM RECHARGES ARE EXPECTED TO INCREASE BY APPROX. 15% (PREVIOUSLY: APPROX. 10%) (2018: EUR 364.0 M).ADJUSTED GROUP EBITDA IS EXPECTED TO INCREASE BY >10% (PREVIOUSLY: APPROX. 10%) (2018: EUR 92.0 M).GUIDANCE ON UNPARTNERED RESEARCH AND DEVELOPMENT EXPENSES REMAINS UNCHANGED AT EUR 30-40 M (2018: EUR 22.9 M).

Evotec And Lygature In Cooperation To Develop Antibacterial Agents

Aug 1 (Reuters) - EVOTEC SE <EVTG.DE>::EVOTEC SE AND LYGATURE ANNOUNCED COOPERATION FOR DEVELOPMENT OF ANTIBACTERIAL AGENTS.TO DO 3 PROGRAMS, 1 TO COMPLETE PHASE I STUDIES, 1 TO INVESTIGATIONAL NEW DRUG (IND) STAGE AND/OR UP TO 2 REACHING CLINICAL DEVELOPMENT CANDIDATE STAGE, BY 2024.IMI, WORLD'S LARGEST PUBLIC-PRIVATE PARTNERSHIP (PPP) IN LIFE SCIENCES, WILL MATCH EVOTEC'S IN-KIND CONTRIBUTION WITH A EUR 12 M GRANT OVER NEXT SIX YEARS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up